Furthermore, we found that miR-665 was only associated with poor survival in BC patients with estrogen receptor (ER)-positive tumor but not in patients with ER-negative tumor in both TCGA and METABRIC databases (Fig. S1B–E). Here, ESR1 is linked to neoplasm.